The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

AI predicts Parkinson’s disease using medical and prescription data, enhancing early diagnosis and research into new ...

Parkinson’s Disease has over 40 wide-ranging symptoms, as per the charity, from tremors and mental health issues to blood pressure changes. Those with Parkin 2 often experience these symptoms at ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

This pivotal study investigates the potential of specialized phototherapy to improve both non-motor and motor symptoms of Parkinson's disease (PD) beyond current best medical care, aiming to ...

21, 2025 — The B vitamin mitigates manganese neurotoxicity, which produces symptoms ... motor function, offering a new therapeutic ... A Risky Business: Why Do Some Parkinson's Disease ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

Movement is key in helping to control symptoms of Parkinson’s disease (PD). To help promote the benefits of cycling as it ...